MSA and COVID-19
Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely. Unfortunately,…
Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely. Unfortunately,…
The third in a series of studies measured cerebrospinal fluid epinephrine pharmacokinetics, nasal mucosa effects, plasma epinephrine pharmacokinetics, and cardiovascular…
May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…
The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….
April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…
March 16, 2020 MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating…
February 17, 2020 Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system…
January 15, 2020 MSA recently made significant upgrades to our office space located within the Frederick Innovation Technology Center. Each…
November 14, 2019 On November 10, 2019, Mr. Michael Mesa, President and CEO of Mesa Science Associates (MSA), announced the…
November 13, 2019 Preclinical Study of Intranasal Epinephrine Administration in Nasal Congestion Model Demonstrated Faster Absorption of Epinephrine in Canines…
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…